CORPORATE

——————— Seed Financing Supports the Transition Toward Clinical Development. In 2019, Odimma Therapeutics secured €2 million in seed funding, combining a €1 million investment led by Cap Innov’Est with €1 million in support from Bpifrance’s Deeptech program. The financing marked a major milestone in the company’s development, providing the resources needed to advance its proprietary personalized cancer immunotherapy platform…